{
    "id": "dbpedia_3409_2",
    "rank": 79,
    "data": {
        "url": "https://sobera-capital.com/news/archive/",
        "read_more_link": "",
        "language": "en",
        "title": "Archive – Sobera Capital",
        "top_image": "https://sobera-capital.com/wp-content/uploads/2021/02/cropped-Sobera_Favicon-32x32.png",
        "meta_img": "https://sobera-capital.com/wp-content/uploads/2021/02/cropped-Sobera_Favicon-32x32.png",
        "images": [
            "https://sobera-capital.com/wp-content/uploads/2016/02/Logo_300px.jpg",
            "https://sobera-capital.com/wp-content/uploads/2016/02/cropped-Header_Bild_1000px_L2.jpg",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/ers_electronic.png",
            "https://sobera-capital.com/wp-content/uploads/2018/02/effrx-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2020/05/CORTUS-1-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2020/05/CORTUS-1-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/ers_electronic.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/tm3.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/ers_electronic.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2018/02/presidio-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/wenzel.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/ers_electronic.png",
            "https://sobera-capital.com/wp-content/uploads/2018/02/effrx-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2018/02/effrx-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2018/02/effrx-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2020/05/CORTUS-1-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2020/05/CORTUS-1-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/wenzel.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/wenzel.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/wenzel.png",
            "https://sobera-capital.com/wp-content/uploads/2018/02/effrx-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/ers_electronic.png",
            "https://sobera-capital.com/wp-content/uploads/2018/02/effrx-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2018/02/presidio-150x150.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/knowis2010.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/sobera_News.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/knowis2010.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/ers_electronic.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/lophius.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/knowis2010.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/lophius.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/sobera_News.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2018/02/myoscience.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/multimmune.png",
            "https://sobera-capital.com/wp-content/uploads/2018/02/myoscience.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/multimmune.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/lophius.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/multimmune.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/ers_electronic.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/ers_electronic.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/biomax.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/biomax.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/sobera_News.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/amicra.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/ers_electronic.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/sobera_News.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/lophius.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/biomax.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/sobera_News.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/lophius.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/amicra.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_OneAccess.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/isarna.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/lophius.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/lophius.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/02_Nanotron.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/cerbomed.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/sobera_News.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/02_Arravasc.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/lophius.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/02_Nanotron.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/07/amicra.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_OneAccess.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/04_Neurotech.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/02_Nanotron.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/02_Nanotron.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_ETH.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/02_Nanotron.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/02_Arravasc.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/02_Nanotron.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/02_Arravasc.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/04_Neurotech.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_Memo.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_OneAccess.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/04_Neurotech.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/sobera_News.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_OneAccess.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_OneAccess.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_OneAccess.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_OneAccess.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/sobera_News.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_Analyticon.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/05_Paratek.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/13_Scaleochip.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/03_OneAccess.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/04_Neurotech.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/13_Scaleochip.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/sobera_News.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/06_Pieris.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_EnOcean.png",
            "https://sobera-capital.com/wp-content/uploads/2016/02/01_ACTB.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://sobera-capital.com/wp-content/uploads/2021/02/cropped-Sobera_Favicon-32x32.png",
        "meta_site_name": "",
        "canonical_link": "https://sobera-capital.com/news/archive/",
        "text": "November 26, 2019\n\nJoint Forces: IBM and Knowis Open New Ways in Platform Banking\n\nNovember 15, 2019\n\nPieris Pharmaceuticals Announces Asthma-focused Translational Research Collaboration\n\nwith the University of Pittsburgh\n\nNovember 15, 2019\n\nERS electronic Announces Microworld as its New Distributor for France, Switzerland and North Africa\n\nNovember 9, 2019\n\nPieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit\n\nwith 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study\n\nNovember 04, 2019\n\nPieris Pharmaceuticals Announces $32 Million Private Placement\n\nand Potential Funding Mechanism for PRS-060 Co-development Opt-in\n\nOctober 25, 2019\n\nImmunoQure AG and Memo Therapeutics AG Announce Collaboration for the\n\nProduction of APS-1 Cognate, Paired Libraries\n\nSeptember 26, 2019\n\nPieris Pharmaceuticals and AstraZeneca Present Multiple Ascending Dose Phase 1b Data for Inhaled IL4-Rα Antagonist AZD1402/PRS-060 at the 2019 European Respiratory Society International Congress\n\nSeptember 19, 2019\n\nEnergy Harvesting in the Nordics: EnOcean Boosts Sales Activities in Northern Europe\n\nSeptember 19, 2019\n\nLophius Biosciences Closes Financing Round To Set New Standard In Tuberculosis Diagnosis\n\nSeptember 11, 2019\n\nMemo Therapeutics Nominates Its First Human-Derived Monoclonal\n\nAntibody To Enter Preclinical Development\n\nJune 04, 2019\n\nKowis Receives Bestseller Award from IBM\n\nMay 22, 2019\n\nPieris Pharmaceuticals and AstraZeneca Present Single- Ascending Dose\n\nPhase 1a Data for Inhaled IL4Rα Antagonist AZD1402/PRS-060\n\nMay 14, 2019\n\nEnOcean Accepted Into Forbes Technology Council\n\nMay 07, 2019\n\nLophius Biosciences Achieves Development Milestone in Establishing\n\nHigh-Performance Tuberculosis Infection Detection Test\n\nMarch 18, 2019\n\nSobera Capital Exits PartMaster\n\nMarch 12, 2019\n\nPieris Pharmaceuticals Reports 2018 Year-End Cash Position and Provides Corporate Update\n\nMarch 05, 2019\n\nMyoscience Announces Agreement to be Acquired by Pacira for up to $220 Million\n\nMarch 04, 2019\n\nSPION Magnetic Nanoparticles. Click on logo for more information.\n\nFebruary 26, 2019\n\nMyoscience Announces Launch of New Smart Tip for iovera System,\n\na Non-Opioid Pain Management Therapy\n\nFebruary 11, 2019\n\nMultimmune's Autologous NK Cell Therapy (ENKASTIMev) Followed By Second-Line PD-1 Inhibition Delivers Long-Term Disease Control In Patient With Lung Cancer. Click on logo for more information.\n\nFebruary 07, 2019\n\nPositive T-Track® CMV Study Results\n\nFebruary 1, 2019\n\nMemo Therapeutics announces the development of a droplet sorter\n\nenabling functional antibody screening in a high-throughput format\n\nJanuary 24, 2019\n\nRadiochemotherapy combined with NK cell transfer followed by second-line\n\nPD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study\n\nJanuary 18, 2019\n\nERS electronic GmbH takes the lead in Fan-Out Panel Level Packaging equipment\n\nmanufacturing with its new thermal debonding tool, the MPDM700\n\nSeptember 4, 2018\n\nPieris Pharmaceuticals Announces Dosing of First Patient in Phase I\n\nCombination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy\n\nJuly 11, 2018\n\nERS Electronic is Announcing Woowon Technology Co., Ltd. as New Sales Channel Partner\n\nMay 15, 2018\n\nBiomax Informatics Software Licensed by Royal DSM\n\nMay 9, 2018\n\nMemo Therapeutics AG Closes Series A2 Financing Round of CHF 5 Million\n\nApril 10, 2018\n\nBiomax Informatics Software Licensed by Global Pharma Company,\n\nBoehringer Ingelheim\n\nApril 3, 2018\n\nSobera Capital Exits AMICRA to ASM Pacific Technologies\n\nApril 3, 2018\n\nASM Pacific Technology Acquires Amicra to Enter the Photonics Market\n\nMarch 13, 2018\n\nERS Electronic Announces That its Industry-Leading AirCool® PRIME Thermal Chuck technology Will Soon be Available For 200 mm Wafer Testing\n\nFebruary 26, 2018\n\nSobera Capital Acquires International Portfolio of Direct Interests from Innoveas\n\nFebruary 16, 2018\n\nPieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares\n\nFebruary 09, 2018\n\nPieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration\n\nFebruary 08, 2018\n\nT-Track® CMV is a Highly Sensitive Immune-Monitoring Tool for Risk Stratification of Renal Transplant Recipients\n\nFebruary 05, 2018\n\nParatek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections\n\nJanuary 18, 2018\n\nParatek Announces Pricing of Public Offering of Common Stock\n\nDecember 7, 2017\n\nPieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program\n\nOctober 12, 2017\n\nBiomax Informatics’ NeuroXM™ Suite Wins Innovation Award\n\nOctober 04, 2017\n\nSobera Capital Exits OneAccess Networks\n\nSeptember 01, 2017\n\nLaunch of the Next Generation T-Track® CMV Immune Monitoring Tool\n\nJuly 17, 2017\n\nParatek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections\n\nJune 27, 2017\n\nPieris Pharmaceuticals Added to the Russell 2000(R) and Russell 3000(R)\n\nIndexes\n\nJune 23, 2017\n\nAMICRA Announces New Headquarter Building\n\nJune 08, 2017\n\nOneAccess Networks enables Telia Company to Launch World's First Commercial 4G Mobile Access for Carrier Ethernet Services\n\nJune 04, 2017\n\nPieris Pharmaceuticals Announces Presentation of Clinical Data for Anemia Drug Candidate, PRS-080\n\nJune 03, 2017\n\nNew Microbiology Data Reinforce Activity of Paratek's Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections\n\nMay 23, 2017\n\nMemo Therapeutics AG announces proof of concept of its huMemoMABTM antibody technology platform\n\nMay 15, 2017\n\nIsarna Presents Positive Clinical Data for ISTH0036 in Advanced Glaucoma\n\nMay 03, 2017\n\nPieris Pharmaceuticals and AstraZeneca Collaborate\n\nApril 05, 2017\n\nClinical Validation of T-Track CMV, a Highly Sensitive Immune-Monitoring Tool\n\nApril 04, 2017\n\nPieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate\n\nApril 03, 2017\n\nParatek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia\n\nMarch 27, 2017\n\nAllergan and Paratek Announce Positive Results From Two Phase 3 Trials\n\nMarch 22, 2017\n\nPieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update\n\nMarch 16, 2017\n\nLophius Biosciences Completes Extension of its Financing Round to €7.36 Million\n\nFebruary 27, 2017\n\nPieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutica\n\nJanuary 18, 2017\n\nParatek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study\n\nJanuary 17, 2017\n\nAndreas Schneider Becomes the New CEO of EnOcean\n\nJanuary 5, 2017\n\nPieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance\n\nNov 22, 2016\n\nFirst Client Project Completed - Validation of MemoMAB Platform\n\nOct 26, 2016\n\nPieris Pharmaceuticals to Receive GLP Tox Milestone Payment in Daiichi Sankyo Collaboration\n\nOct 11, 2016\n\nEnOcean adds 2.4 GHz BLE modules to its product portfolio\n\nOct 11, 2016\n\nParatek, U.S. Department of Defense Enter Research Agreement to Study Omadacycline Against Biodefense Pathogens\n\nSep 27, 2016\n\nIntelligent Building expert becomes new President of EnOcean Inc.\n\nSep 26, 2016\n\nPieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343\n\nSep 26, 2016\n\nWorld-first Set of Productivity Tools for precise RTLS\n\nSep 17, 2016\n\nPharmaceuticals and medical technology will go hand in hand in future – DESITIN and cerbomed sign distribution agreement\n\nSep 14, 2016\n\nMemo Therapeutics made it to the top 100 of Swiss startups for the second time in a row\n\nAug 16, 2016\n\nSobera Capital Takes Over Management of Private Equity Vehicles of Bavarian Savings Banks\n\nAug 15, 2016\n\nParatek Initiates Phase 3 Study of Oral-only Omadacycline in ABSSSI\n\nAug 10, 2016\n\nPieris Pharmaceuticals Reports Financial Results and Provides Corporate Update\n\nfor the Second Quarter Ended June 30, 2016\n\nJul 31, 2016\n\nArraVasc receives FDA 510(k) clearance for Pirouette 035 PTA catheter\n\nJul 26, 2016\n\nLophius Biosciences Closed Financing Round of €4.25 Million to Expand Diagnostic\n\nDevelopments into Tuberculosis and to Strengthen Marketing Activities\n\nJun 27, 2016\n\nParatek Announces Closing of Common Stock Offering and Exercise in Full\n\nof Underwriters’ Option to Purchase Additional Shares\n\nJun 13, 2016\n\nNanotron starts shipping UWB Development Kit\n\nJun 15, 2016\n\nFirst rabbit based client project started\n\nJun 8, 2016\n\nPieris Pharmaceuticals Announces Closing of $16.5 Million Private Placement\n\nMay 24, 2016\n\nAMICRA to Provide Precision Die Attach System to Fabrinet in Silicon Valley\n\nMay 17, 2016\n\nHighlights assessment and implementation challenges operators face together with\n\nprevailing options for fast and open network virtualization\n\nMay 15, 2016\n\nSwiss government sponsored CTI/KTI R&D project\n\nApr 29, 2016\n\nNeurotech Announces Renewed Focus on NT‐501 (CNTF)\n\nEncapsulated Cell Therapy Clinical Programs\n\nMar 17, 2016\n\nPieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data\n\nfor Its Lead Bispecific Immuno-Oncology Drug Candidate, PRS-343\n\nMar 10, 2016\n\nEnOcean Kinetic Power Conquers the World\n\nMar 1, 2016\n\nHuman antibodies in the treatment of Ebola\n\nFeb 29, 2016\n\nProof of concept for rabbit based MemoMAB process\n\nFeb 24, 2016\n\nnanoLOX - The world-First Dual Mode Location Device\n\nFeb 23, 2016\n\nElement14 Unveils Two Self-Powered IoT Starter Kits\n\nwith EnOcean and IBM Technologies\n\nJan 6, 2016\n\nParatek Accelerates Timing for Projected Reporting of Top-Line Data\n\nfor Omadacycline Phase 3 Skin Trial\n\nDec 21, 2015\n\nSwarm Location Made Simple - Nanotron And Omnisense Cooperate on Easy-To-Use Location Solutions\n\nDec 11, 2015\n\nMillenicom Sold to EWE Turkey\n\nDec 8, 2015\n\nPieris Pharmaceuticals announces First Cancer Immunotherapy Collaboration\n\nNov 30, 2015\n\nPieris Pharmaceuticals Achieves Payment Milestone in Sanofi Collaboration\n\nNov 30, 2015\n\nNanotron Expands Sales Channels in South Africa\n\nNov 19, 2015\n\nPieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program\n\nNov 18, 2015\n\nEnOcean and ASUS company AAEON partner to bring energy harvesting wireless technology to makers\n\nNov 9, 2015\n\nParatek Initiates Omadacycline Phase 3 Clinical Study in Community Acquired Bacterial Pneumonia (CABP)\n\nNov 4, 2015\n\nParatek Receives FDA Fast Track Designation for Omadacycline\n\nOct 28, 2015\n\nArraVasc receives CE Mark Approval for Pirouette 035 PTA Catheter\n\nOct 22, 2015\n\nBattery-Free, Wireless Switching for all Platforms with EnOcean Click\n\nOct 9, 2015\n\nLocation-Aware Wireless Sensor Solutions for I4.0\n\nSep 30, 2015\n\nArraVasc Receives FDA 510(k) Clearance for Pirouette 018 PTA Catheter\n\nSep 30, 2015\n\nPositive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program\n\nSep 21, 2015\n\nPieris Pharmaceuticals Presents Positive Preclinical Data on Lead Bispecific Immuno-Oncology Program\n\nSep 17, 2015\n\nParatek's Omadacycline Demonstrates Broad Spectrum Activity in Pathogens\n\nSep 15, 2015\n\nPieris Pharmaceuticals' Collaborator Presents Promising Preclinical Data\n\nSep 2, 2015\n\nNeurotech Announces First Patient Enrolled in Novel Anti VEGF Encapsulated Cell Therapy Study\n\nJul 28, 2015\n\nPieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock\n\nJul 22, 2015\n\nMemo Therapeutics Closes Series A Financing Round\n\nJul 8, 2015\n\nPieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics\n\nJul 7, 2015\n\nPieris Pharmaceuticals Closes Public Offering of Common Stock\n\nJun 30, 2015\n\nPieris Pharmaceuticals Prices Public Offering of Common Stock\n\nJun 23, 2015\n\nParatek Doses First Patient in Phase 3 Clinical Trial of Omadacycline in Acute Skin and Skin Structure Infections\n\nJun 10, 2015\n\nPieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia\n\nMay 14, 2015\n\nPieris Pharmaceuticals Appoints Immuno-Oncology Expert\n\nMay 12, 2015\n\nPieris Pharmaceuticals Appoints Former Celgene and Sanofi Executive\n\nMay 5, 2015\n\nEllipse Projects Partners with OneAccess to Launch ONE1540 CPE Router in Thailand\n\nMar 30, 2015\n\nPieris Pharmaceuticals and The University of Melbourne Receive\n\nResearch Grant to Advance Immunological Diseases Program\n\nMar 30, 2015\n\nNeurotech Announces FDA Acceptance of IND\n\nMar 5, 2015\n\nEnEnOcean Launches Complete Wireless LED Control System\n\nFeb 17, 2015\n\nEnEnOcean Launches Complete Wireless LED Control System\n\nJan 6, 2015\n\nParatek to Receive $4 Million Payment From Actavis With Initiation of Phase 3 Trial of Sarecycline\n\nDec 23, 2 014\n\nPieris Pharmaceuticals, Inc completes private placement, raises $13.6M\n\nDec 18, 2014\n\nSobera Capital's portfolio company Pieris goes public\n\nDec 18, 2014\n\nPieris Pharmaceuticals, Inc goes public, raises $ 12.2 million\n\nDec 11, 2014\n\nPieris initiates phase I clinical trial for Anticalin® to treat Anemia\n\nDec 8, 2014\n\nPieris achieves GLP tox milestone payment in Daiichi Sankyo collaboration\n\nto develop Anticalin® therapeutics\n\nDec 3, 2014\n\nParatek Pharmaceuticals announces appointment of Douglas Pagán as\n\nChief Financial Officer\n\nDec 1, 2014\n\nPieris achieves second preclinical milestone in Sanofi collaboration\n\nNov 12, 2014\n\nPieris appoints Michael Richman as supervisory board member\n\nNov 4, 2014\n\nParatek Pharmaceuticals strengthens management team\n\nNov 3, 2014\n\nLime Link selects OneAccess Networks for their satellite VPN services\n\nOct 30, 2014\n\nParatek Pharmaceuticals completes merger with Transcept Pharmaceuticals\n\nOct 9, 2014\n\nOneAccess and Axiros Partner to increase agility of telco operators via Managed Network Service Delivery Platform\n\nOct 2, 2014\n\nOneAccess Networks and SYNNEX Corporation enter into distribution agreement\n\nSep 22, 2014\n\nStart-up expert becomes new CEO of EnOcean\n\nSep 22, 2014\n\nOneAccess launches LTE enabled multi-service access router platform\n\nJul 3, 2014\n\nSobera Capital exits AnalytiCon\n\nJul 3, 2014\n\nBRAIN in partnership with AnalytiCon Discovery\n\nJul 1, 2014\n\nTranscept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement\n\nJul 1, 2014\n\nParatek appoints Michael Bigham as Chairman and CEO and promotes Evan Loh to President and CMO\n\nJun 23, 2014\n\nPieris achieves milestone payment in Daiichi Sankyo collaboration to develop Anticalin therapeutics\n\nJun 17, 2014\n\nScaleo chip and IFP Energies nouvelles unveil OLEA in a plug-in hybrid car\n\nMay 28, 2014\n\nEnergy harvesting wireless product portfolio dedicated for China\n\nMay 19, 2014\n\nTokheim selects OneAccess to optimize business-critical international network\n\nApr 15, 2014\n\nEnOcean introduces batteryless wireless solutions to the Japanese market\n\nApr 11, 2014\n\nQuinton oswald appointed Chief executive officer of Neurotech Pharmaceuticals\n\nMar 31, 2014\n\nEnOcean self-powers 2.4 GHz radio with kinetic energy\n\nMar 10, 2014\n\nScaleo chip announces OLEA samples availability\n\nFeb 19, 2014\n\nSobera Capital's portfolio company ACT Biotech sells oncology assets to Eddingpharm for up to $95 million\n\nFeb 10, 2014\n\nPieris achieves preclinical milestone payment in Sanofi collaboration\n\nJan 13, 2014\n\nPieris achieves fourth milestone payment in Daiichi Sankyo collaboration to develop Anticalin therapeutics\n\nJan 8, 2014\n\nNXP and EnOcean use NFC to simplify energy harvesting wireless in the smart home"
    }
}